Table 2
Integrated analysis comparing the number of patients who had asthma exacerbations according to three definitions among patients who received zafirlukast 20 mg twice daily or placebo
| Exacerbations that: |
Zafirlukast (n = 972) |
Placebo (n = 692) |
Odds ratio | 95% confidence interval | p value | p value (Breslow-Day test) |
| Led to withdrawal | 26 (2.7) | 38 (5.5) | 0.45 | 0.26 to 0.76 | 0.003 | 0.833 |
| Required additional asthma treatment | 33 (3.4) | 53 (7.7) | 0.47 | 0.30 to 0.74 | 0.001 | 0.477 |
| Required oral steroid treatment | 31 (3.2) | 45 (6.5) | 0.53 | 0.32 to 0.86 | 0.010 | 0.702 |
-
Values are no. (%).
